

APPENDIX A: CLAIMS AFTER THE RESPONSE TO FINAL OFFICE ACTION

1. A homoconjugate of two or more monoclonal antibodies, wherein the homoconjugate comprises a monoclonal antibody that does not comprise an Fc region, wherein the homoconjugate has anti-neoplastic activity and wherein said monoclonal antibody has substantially no anti-neoplastic activity in an unconjugated form.
2. [Cancelled]
3. [Cancelled]
4. The homoconjugate of claim 3, wherein the homoconjugate comprises an anti-CD19, anti-CD20, anti-CD21, anti-CD22, anti-breast tumor, anti-ovarian tumor, anti-prostate tumor, anti-lung tumor, or anti- α Her2 monoclonal antibody.
5. The homoconjugate of claim 3, wherein the homoconjugate comprises an anti-Her2 monoclonal antibody.
6. [Cancelled]
7. The homoconjugate of claim 1, further defined as a homodimer.
8. The homoconjugate of claim 1, wherein the homoconjugate comprises a monoclonal antibody that is an IgG monomer.
9. The homoconjugate of claim 8, wherein the IgG is a mammalian IgG.
10. [Cancelled]
11. A method of making a homoconjugate of two or more monoclonal antibodies, wherein the homoconjugate comprises a monoclonal antibody that does not comprise an Fc region, comprising:

obtaining a first monoclonal antibody that does not comprise an Fc region;
obtaining a second monoclonal antibody that does not comprise an Fc region; and
conjugating the first monoclonal antibody to the second monoclonal antibody, wherein
the first and second monoclonal antibodies have anti-neoplastic activity in a conjugated
form and have substantially no anti-neoplastic activity in an unconjugated form.

12. [Cancelled]

13. [Cancelled]

14. [Cancelled]

15. [Cancelled]

16. The method of claim 14, wherein the monoclonal antibody is an anti-CD19, anti-CD20, anti-CD21, anti-CD22, anti-breast tumor, anti-ovarian tumor, anti-prostate tumor, anti-lung tumor, or anti- α Her2 monoclonal antibody.

17. The method of claim 14, wherein the monoclonal antibody is an anti-Her2 monoclonal antibody.

18. [Cancelled]

19. [Cancelled]

20. [Cancelled]

21. The method of claim 11, wherein the homoconjugate is further defined as a homodimer.

22. The method of claim 11, wherein the homoconjugate comprises a monoclonal antibody that is an IgG monomer.

23. The method of claim 11, wherein the homoconjugate comprises a mammalian monoclonal antibody.

24. [Cancelled]

25. The method of claim 11, further consisting of:
obtaining a third monoclonal antibody; and
conjugating the third monoclonal antibody to the homoconjugate.

26-42. [Cancelled]

43. A pharmaceutical composition comprising a homoconjugate comprising a monoclonal antibody and a pharmaceutically acceptable carrier, wherein the monoclonal antibody does not comprise an Fc region and wherein the monoclonal antibody has anti-neoplastic activity in a conjugated form and has substantially no anti-neoplastic activity in an unconjugated form.

44. [Cancelled]

45. [Cancelled]

46. The pharmaceutical composition of claim 43, wherein the monoclonal antibody is an anti-CD19, anti-CD20, anti-CD21, anti-CD22, anti-breast tumor, anti-ovarian tumor, anti-prostate tumor, anti-lung tumor, or anti- α Her2 monoclonal antibody.

47. The pharmaceutical composition of claim 43, wherein the monoclonal antibody is an anti- α Her2 monoclonal antibody.

48. [Cancelled]

49. The pharmaceutical composition of claim 43, wherein the homoconjugate is further defined as a homodimer.

50. The pharmaceutical composition of claim 43, wherein the homoconjugate comprises a monoclonal antibody that is an IgG monomer.

51. The pharmaceutical composition of claim 43, wherein the homoconjugate comprises a mammalian monoclonal antibody.

52. [Cancelled]